written on 07.02.2018

Switzerland Pharma Report


Building on our two recent reports on Switzerland, this special Part III edition of Healthcare & Life Sciences Review casts a broad eye over the myriad of niches and specializations within the sector in which Switzerland and Swiss companies excel.


Notable topicalities include Novartis Oncology’s ground-breaking CAR-T therapy; how SwissMedic is leading the world in terms of regulatory innovation; the story of Actelion’s acquisition by J&J and the subsequent emergence of a new entity – Idorsia; Switzerland’s emergence as a destination for elite-level outsourced manufacturing; and the country’s embrace of digitally disruptive technologies throughout the pharmaceutical value chain, as evinced by SwissPost’s use of drones for drug deliveries.

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here